Some examples of promising targets that lack robust companion biomarkers in SCLC are those related to inhibitors of polo-like kinase 1 (PLK1) [3,4] or cyclin-dependent kinases (CDKs) [2]. The gene discussed is PLK1; the disease is small cell lung carcinoma.